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Abstract
Summary Limited data exist on the efficacy of long-term ther-
apies for osteoporosis. In osteoporotic postmenopausal wom-
en receiving denosumab for 7 years, nonvertebral fracture
rates significantly decreased in years 4–7 versus years 1–3.
This is the first demonstration of a further benefit on fracture
outcomes with long-term therapy for osteoporosis.
Introduction This study aimed to evaluate whether
denosumab treatment continued beyond 3 years is associated
with a further reduction in nonvertebral fracture rates.
Methods Participants who completed the 3-year placebo-
controlled Fracture REduction Evaluation of Denosumab in
Osteoporosis every 6 Months (FREEDOM) study were invited
to participate in an open-label extension. The present analysis
includes 4,074 postmenopausal women with osteoporosis
(n=2,343 long-term; n=1,731 cross-over) who enrolled in the
extension, missed ≤1 dose during their first 3 years of
denosumab treatment, and continued into the fourth year of
treatment. Comparison of nonvertebral fracture rates during
years 1–3 of denosumab with that of the fourth year and with
the rate during years 4–7 was evaluated.
Results For the combined group, the nonvertebral fracture rate
per 100 participant-years was 2.15 for the first 3 years of
denosumab treatment (referent) and 1.36 in the fourth year
(rate ratio [RR]=0.64; 95 % confidence interval (CI)=0.48
to 0.85, p=0.003). Comparable findings were observed in
the groups separately and when nonvertebral fracture rates
during years 1–3 were compared to years 4–7 in the long-
term group (RR=0.79; 95 % CI=0.62 to 1.00, p=0.046).
Fracture rate reductions in year 4 were most prominent in
subjects with persisting low hip bone mineral density (BMD).
Conclusions Denosumab treatment beyond 3 years was asso-
ciated with a further reduction in nonvertebral fracture rate
that persisted through 7 years of continuous denosumab ad-
ministration. The degree to which denosumab further reduces
nonvertebral fracture risk appears influenced by the hip bone
density achieved with initial therapy.
Keywords Denosumab . Fracture threshold . Hip bone
mineral density . Long-term osteoporosis therapy .
Nonvertebral fracture . Treatment to goal
Introduction
Nonvertebral fractures, including hip fractures, represent 75%
of all fragility fractures related to osteoporosis and are associ-
ated with significant morbidity and mortality [1–3]. In ran-
domized placebo-controlled trials, nonvertebral fracture risk
reduction in the range of 20 %–30 % over 3 years has been
shown with denosumab and some (zoledronic acid,
* S. Ferrari
Serge.Ferrari@unige.ch
1 Geneva University Hospital, Geneva, Switzerland
2 McMaster University, Hamilton, ON, Canada
3 Bern University Hospital, Bern, Switzerland
4 Amgen Inc., Thousand Oaks, CA, USA
5 Colorado Center for Bone Research, Lakewood, CO, USA
6 University of Liège, Liège, Belgium
7 Karolinska Institutet, Södersjukhuset, Stockholm, Sweden
8 University of British Columbia, Vancouver, BC, Canada
9 New Mexico Clinical Research & Osteoporosis Center,
Albuquerque, NM, USA
Osteoporos Int (2015) 26:2763–2771
DOI 10.1007/s00198-015-3179-x
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
76
34
0 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
alendronate, risedronate), though not all, bisphosphonates
[4–7].
Only a few studies evaluating the long-term efficacy of
osteoporosis drugs are available. Bisphosphonate treatment
extended beyond 3 years is generally associated with a plateau
in hip bone mineral density (BMD) gains and fracture rates
that remain comparable to those observed during the first
3 years; however, the number of subjects in these extension
studies is limited, and evidence for further reduction in
nonvertebral fracture rates with continued bisphosphonate
therapy has not been reported [8–10]. Hence, while treatment
with a bisphosphonate for more than 3 years may seem logical
to prevent further deterioration of skeletal integrity in those
who remain at high risk of fracture, the actual benefit of long-
term antiresorptive (bisphosphonate) therapy has been
questioned [11]. Larger studies are therefore needed to evalu-
ate the fracture outcomes of long-term treatment for
osteoporosis.
Denosumab (Prolia®, Amgen Inc., Thousand Oaks, CA) is
a fully human monoclonal antibody that binds with high affin-
ity and specificity to RANK ligand and prevents the formation,
function, and survival of osteoclasts [12, 13]. In the pivotal
Fracture REduction Evaluation of Denosumab in Osteoporosis
every 6 Months (FREEDOM) trial, denosumab reduced the
incidence of vertebral, nonvertebral, and hip fractures over
3 years compared with placebo [7]. The effect of long-term
denosumab treatment on fracture risk is being evaluated for a
total of 10 years in an ongoing open-label FREEDOM exten-
sion. Six years of denosumab treatment produced continued
increases in BMD, maintained the dynamic reduction in bone
turnover markers, and was associated with a persistent low
incidence of fractures, which was significantly lower than in
a control group of modeled virtual twins [14, 15].
To further evaluate long-term fracture rates using each sub-
ject as her own control, we considered the subjects who en-
rolled in the FREEDOM extension, who missed no more than
one denosumab injection during their first 3 years of
denosumab treatment (in FREEDOM for those in the original
denosumab group or in the extension for those in the original
placebo group), and who continued into their fourth year of
denosumab treatment. By this time, women in the original
FREEDOM denosumab group (long-term subjects) had com-
pleted up to 7 years of treatment. We hypothesized that
denosumab treatment continued beyond year 3 was associated
with a further reduction in nonvertebral fracture rate compared
with the first 3 years of treatment. Since previous reports doc-
umented that gains in hip BMD accounted for a large propor-
tion of the effect of denosumab to reduce nonvertebral frac-
tures [16], we also explored the relationship between hip
BMD level attained at the end of 3 years of denosumab ad-
ministration—as measured by femoral neck T-score—and
subsequent nonvertebral fracture rates with longer-term
denosumab administration.
Materials and methods
Study design and procedures
Both the FREEDOM (ClinicalTrials.gov: NCT00089791) and
the extension (ClinicalTrials.gov: NCT00523341) study de-
signs and main results have been previously described [7,
14, 15]. In summary, FREEDOM was a phase 3, multination-
al, randomized, double-blind, placebo-controlled, 3-year
study in postmenopausal women aged 60–90 years who had
a lumbar spine or total hip T-score <−2.5 at either location and
≥−4.0 at both skeletal sites. Participants were randomly
assigned to receive placebo or 60 mg denosumab (Prolia®,
Amgen Inc., Thousand Oaks, CA) subcutaneously every
6 months for 3 years and were required to take calcium
(≥1 g) and vitamin D (≥400 IU) daily. Women who completed
the FREEDOM study (i.e., completed their 3-year visit, did
not miss >1 dose of the investigational product [IP]) and did
not receive other medications known to affect bone metabo-
lismwere invited to enroll in an extension study, during which
all participants received open-label denosumab 60 mg subcu-
taneously every 6 months with daily calcium and vitamin D
[7]. Subjects who were randomized to denosumab in FREE
DOM and continued denosumab treatment in the extension
constitute the long-term group and subjects who were ran-
domized to placebo treatment for 3 years and then started
denosumab at the beginning of the extension constitute the
cross-over group. By design, subjects were enrolled in the
extension provided they had received at least five out of six
denosumab or placebo doses over 3 years in FREEDOM. To
ensure comparability between groups in the present analysis,
we evaluated only those subjects in the cross-over group who
received at least five out of six doses in their first 3 years of
denosumab treatment and continued into their fourth year (the
same criterion required for subjects originally assigned to
denosumab to be eligible for and then enter the extension).
The study protocol was approved by an institutional review
board or ethics committee for each investigative site. Partici-
pants provided written informed consent.
Study visits occurred at baseline and every 6 months for the
duration of the extension study. The study procedures were
previously described [15] and followed the same collection
rigor as during FREEDOM. All nonvertebral fractures re-
quired confirmation by diagnostic imaging or a radiologist’s
report and were adjudicated by a central vendor (Synarc), as
previously described [7]. Hip BMD, as measured by dual-
energy X-ray absorptiometry, was obtained in all subjects in
FREEDOM, as previously reported [7, 17].
Statistical analyses
Analyses were implemented on subjects who enrolled in the
FREEDOM extension, who missed ≤1 dose of denosumab
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during their first 3 years of denosumab treatment, and who
continued into their fourth year of denosumab treatment (n=
2,343 long-term, n=1,731 cross-over). Yearly incremental
estimates of the incidence of nonvertebral fractures were
calculated using Kaplan-Meier methodology for both groups
separately. Nonvertebral fracture rates per 100 participant-
years during the first 3 years and the subsequent fourth year
of denosumab treatment were computed and compared
based on the rate ratio (year 4 versus years 1–3) in the
long-term and cross-over groups separately and combined.
For the long-term group, the nonvertebral fracture rate be-
tween years 4–7 of denosumab treatment also was computed
and compared with the rate during the first 3 years (years 4–
7 versus years 1–3).
Nonvertebral fracture rates (per 100 participant-years),
rate ratios, and 95 % confidence intervals (CIs) were com-
puted by generalized estimating equation Poisson regression.
Rate ratios were adjusted for age, total hip T-score, weight,
and history of nonvertebral fractures at the start of
denosumab treatment (i.e., FREEDOM baseline for the
long-term group and extension study baseline for the
cross-over group). The treatment group variable was includ-
ed in the model for the combined analysis.
Reductions in nonvertebral fracture rates during the
fourth year versus years 1–3 of denosumab treatment were
also evaluated in the combined group, based on the femoral
neck T-score attained after the first 3 years of denosumab
administration, for each of the clinically established and
used densitometric categories (osteoporosis, low bone densi-
ty, and normal) using the statistical methods described
above.
Results
Study participants
Of 5,928 women eligible for the extension study, 4,550 (77%)
enrolled (n=2,343 long-term; n=2,207 cross-over). Of these,
4,074 women (n=2,343 long-term; n=1,731 cross-over)
missed ≤1 dose of denosumab in their first 3 years of
denosumab treatment, continued into the fourth year of treat-
ment, and were included in this analysis, representing up to
7 years of denosumab treatment in the long-term group and
4 years of denosumab treatment in the cross-over group
(Fig. 1).
Participant characteristics at FREEDOM baseline for the
cohort examined here were similar to those of the original
FREEDOM population (Table 1). A larger proportion of
cross-over participants were ≥75 years old at the start of
denosumab treatment, as the study had proceeded for 3 years
from the original FREEDOM study baseline.
Yearly incidences of nonvertebral fractures
The yearly nonvertebral fracture incidences during the first
3 years of denosumab were similar in both the cross-over
and long-term groups with an observed decrease in fracture
incidence in year 4 for both groups (Fig. 2). Analysis of the
long-term completers group (N=1,867) demonstrated similar
results with a decrease in fracture incidence between years 3
(2.0 %) and 4 (1.2 %). There was also a low incidence of year-
after-year hip fractures with long-term denosumab treatment
in the FREEDOM extension of 0.3 % or less every year after
the initial 3 years of denosumab administration.
For the entire cohort of women receiving denosumab, the
nonvertebral fracture rate per 100 participant-years was re-
duced by 36 % (rate ratio=0.64; p=0.003) in year 4 compared
with the first 3 years (Fig. 3a). A reduction of 49% (rate ratio=
0.51; p=0.005) in the nonvertebral fracture rate for year 4
compared with years 1–3 was observed in the cross-over
group (Fig. 3b). In the long-term group (i.e., those who have
received up to 7 years of denosumab), the nonvertebral frac-
ture rate was reduced by 25 % (rate ratio=0.75; p=0.127) in
year 4 compared with years 1–3; a similar reduction of 21 %
(rate ratio=0.79; p=0.0046) was observed when the
nonvertebral fracture rate during years 4–7 was compared
with years 1–3 (Fig. 3c).
We next evaluated the influence of the BMD level attained
after 3 years of denosumab treatment on the subsequent
nonvertebral fracture risk reduction in the combined group.
In subjects whose femoral neck T-scores remained ≤−2.5, a
significant further reduction in nonvertebral fractures was ob-
served in year 4 (rate ratio=0.37; p=0.008; Fig. 4). A further,
but less pronounced, reduction in the nonvertebral fracture
rate was also observed in subjects with T-scores >−2.5 and
<−1.0 but not in subjects with T-scores ≥−1.0 (Fig. 4).
Similar observations were noted when total hip T-score was
used instead of femoral neck T-score, with rate ratios of 0.85
(0.46–1.60) for the ≤−2.5 group, 0.47 (0.30–0.73) for the
>−2.5 to <−1.0 group, and 1.22 (0.67–2.25) for the ≥−1.0
group. The rate ratio of 0.85 did not reach significance which
may have been the result of the small number of subjects (N=
483) and the low number of fractures (n=12) in this subgroup.
Discussion
With 4,074 participants, the cohort forming the basis of this
report represents more than 50 % of the original FREEDOM
study subjects and is the largest extension study to date in the
field of osteoporosis. Notably, despite aging of the subjects,
the nonvertebral fracture rate during year 4 was significantly
further decreased compared with the first 3 years of
denosumab treatment. This pattern was observed in the overall
cohort and similarly in both the subjects who received
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denosumab for 7 years, starting in FREEDOM, and for the
group who started denosumab 3 years later, allowing a con-
firmatory evaluation. Moreover, the nonvertebral fracture rate
was significantly lower in years 4–7 compared with years 1–3
in subjects who received denosumab for 7 years. This consti-
tutes the first observation of a further benefit of an
Enrolled in FREEDOM
7808
Randomized to Placebo
3906
Randomized to Denosumab
3902
Completed Study
3206
Eligible for EXTENSION
2880
Completed Study
3272
Eligible for EXTENSION
3048
Missed >1 dose
denosumab during
years 1−3 of
EXTENSION or
did not continue
into year 4
476
Included in NVFX
Analysis Cohort
1731
Included in NVFX
Analysis Cohort
2343
Enrolled in EXTENSION
Cross-over Denosumab
2207
Enrolled in EXTENSION
Long-term Denosumab
2343*
Did not enroll in
EXTENSION
673
Did not enroll in
EXTENSION
707
Discontinued Study
700
Discontinued Study
630
Fig. 1 Subject disposition in the
FREEDOM study and its
extension and the nonvertebral
fracture analysis. Subjects
included in the nonvertebral
fracture analysis cohort enrolled
in the FREEDOM extension,
missed ≤1 dose of denosumab
during their first 3 years of
denosumab treatment (whether
during FREEDOM or the
extension), and continued their
fourth year of denosumab
treatment. Gray boxes indicate
subjects receiving denosumab.
Asterisk: Two women who
discontinued denosumab also
entered the extension in the long-
term denosumab group. NVFX =
nonvertebral fractures
Table 1 Baseline demographics
This study cohort
Full FREEDOM
population at baseline
N=7,808
NVFX cohort at
FREEDOM baseline
N=4,074
Long-term subjects at
FREEDOM baselinea
N=2,343
Cross-over subjects at
extension baselinea
N=1,731
Age, years 72.3 (5.2) 71.6 (4.9) 71.9 (5.0) 74.3 (4.9)
Age groups – n (%)
≥65 years 7,394 (94.7) 3,819 (93.7) 2,209 (94.3) 1,681 (97.1)
≥75 years 2,471 (31.6) 1,082 (26.6) 662 (28.3) 842 (48.6)
Years since menopause 24.2 (7.5) 23.4 (7.2) 23.7 (7.3) 26.1 (7.2)
Prevalent vertebral fractures – n (%) 1,844 (23.6) 927 (22.8) 559 (23.9) 421 (24.3)
Prevalent nonvertebral fractures
at age ≥55 – n (%)
2,340 (30.0) 1,198 (29.4) 702 (30.0) 578 (33.4)
Lumbar spine T-score −2.83 (0.69) −2.84 (0.67) −2.83 (0.67) −2.83 (0.75)
Total hip T-score −1.90 (0.81) –1.84 (0.79) −1.85 (0.79) −1.92 (0.80)
Femoral neck T-score −2.16 (0.72) −2.10 (0.71) −2.11 (0.71) −2.13 (0.71)
CTXb (ng/mL) – median (Q1, Q3) 0.516 (0.389, 0.702) 0.533 (0.355, 0.674) 0.505 (0.357, 0.700) 0.496 (0.413, 0.662)
P1NPb (μg/L) – median (Q1, Q3) 46.5 (36.0, 61.2) 46.2 (32.6, 59.5) 46.2 (31.5, 56.8) 48.6 (35.0, 62.2)
Data are means with standard deviations unless otherwise noted
BMD bone mineral density, CTXC-terminal telopeptide of type 1 collagen,N number of participants enrolled in the extension study, NVFX nonvertebral
fractures, P1NP procollagen type 1 N-terminal propeptide
a Represents characteristics at the time of denosumab treatment start
b Data are from participants who were included in the bone turnover marker substudy
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antiresorptive therapy on nonvertebral fractures beyond
3 years of initial administration.
Extension studies with other antiresorptive drugs have not
shown increases in hip BMD or incremental reductions in
nonvertebral fracture rates beyond those observed in the first
few years of treatment. For example, results from the Vertebral
Efficacy With Risedronate Therapy-North America (VERT-
NA) trial with risedronate found no significant reduction in
the rate of nonvertebral fractures in 2 years of additional
risedronate treatment versus the first 3 years of treatment
[10]. Similarly, the Fracture Intervention Trial Long-Term Ex-
tension (FLEX) study did not find a significant difference
between the cumulative risk of nonvertebral fractures for post-
menopausal women continuing alendronate for 5 more years
beyond the initial 5 years of treatment [9, 18]. More recently,
the extension of the Health Outcomes and Reduced Incidence
with Zoledronic Acid Once Yearly-Pivotal Fracture Trial
(HORIZON-PFT) documented that 6 years of treatment with
zoledronic acid resulted in no significant differences in
nonvertebral fracture incidence comparedwith the first 3 years
of treatment nor compared with placebo during the extension
[8]. Although nonvertebral fracture rates in the extension stud-
ies with alendronate and zoledronic acid were reported for
those women who entered the extension and therefore were
applicable to only a subset of those enrolled in the 3-year
pivotal studies, the rates of nonvertebral fracture in the first
3 years were similar to those seen through the completion of
both extension studies [4–6, 19]. These extension studies were
not adequately powered for nonvertebral fracture endpoints.
Data on nonvertebral fractures with long-term denosumab
treatment appear to show a different pattern. Indeed, our
analyses suggest that continuing denosumab treatment be-
yond 3 years reduces the nonvertebral fracture rate compared
with the first 3 years of treatment. Denosumab effects that may
contribute to this distinctive observation include documented
rapid, marked, and sustained reductions in bone resorption
markers following each denosumab dose, and progressive
gains in BMD reported with up to 8 years of continuous
denosumab administration, decreases in cortical porosity with
corresponding increases in cortical bone mass, and increases
in cortical and trabecular strength as detailed with denosumab
in clinical and animal studies [14, 20–26].
In our study, the mean age of women starting denosumab
was 72 years for the long-term group and 74 years for those
starting denosumab in the cross-over extension group, popula-
tions in which one would expect an increasing risk of fracture
over time due to the skeletal deterioration associated with ag-
ing [27, 28]. Yet, long-term treatment with denosumab was
instead associated with further nonvertebral fracture risk reduc-
tion over that documented during the first 3 years of therapy.
Importantly, the pattern of decrease was similar in both groups,
despite the older age of the women in the cross-over group.
The risk of a fracture is dependent on the amount and
distribution of the bone mass at the skeletal site as well as
the frequency and characteristics of the associated trauma, as
exemplified by the variable forces that are associated with
each fall [29]. There are no biological reasons to suspect an
effect of denosumab on fall risk or characteristics of falling,
whereas continued BMD increases are observed over time
with denosumab treatment. Thus, it is plausible that the further
reduction in fractures observed after 3 years of denosumab
administration could be attributed to a larger proportion of
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Fig. 2 Yearly incidence of
nonvertebral fractures in the post
hoc analysis participants. aYearly
incidence of nonvertebral
fractures through 4 years of
denosumab treatment for the
cross-over group. b Yearly
incidence of nonvertebral
fractures through 7 years for the
long-term denosumab group in
the long-term participants.
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≥1 nonvertebral fracture
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subjects achieving a BMD value needed to reduce the factor of
risk for fracture [30].
Acknowledging that factors such as actual change in
BMD, body mass index, bone turnover rate, genetic predis-
position, and frailty also contribute to fracture risk in the
individual patient, our analysis found that fracture reductions
observed in year 4 and beyond were correlated with hip
BMD attained after 3 years of denosumab. Those subgroups
of subjects for whom BMD remained low after 3 years of
denosumab treatment had a documented additional benefit,
whereas additional nonvertebral fracture risk reductions were
not observed in those who had attained a normal bone
density level. One explanation may be that there is a densi-
tometric inflection point above which further gains in bone
density are no longer associated with corresponding addi-
tional fracture reductions. Our data suggest that this BMD
level lies between a T-score of −2.5 and −1.0, a concept also
substantiated by recent work combining BMD and femoral
strength by finite element analysis [31]. These data also
support the concept that further fracture risk reduction may
be related to continued increases in hip BMD; in the original
FREEDOM trial, the change in hip BMD explained a con-
siderable amount of the reduction in nonvertebral fracture
risk [16].
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Fig. 3 Nonvertebral fracture rate
ratios. a All denosumab-treated
participants. b Cross-over
participants. c Long-term
participants. N = number of
subjects who completed FREE
DOM (i.e., completed their 3-year
visit and did not discontinue IP),
missed ≤1 dose of IP in FREE
DOM, and who enrolled in the
extension. In addition, cross-over
subjects completed 3 years of the
extension and missed ≤1 dose of
denosumab during the first
3 years of the extension. Fracture
rates and rate ratios were obtained
using generalized estimating
equation Poisson models; fracture
rates are per 100 participant-
years. Rate ratios relative to the
first 3 years of denosumab
treatment were adjusted for age,
total hip T-score, weight, and
history of nonvertebral fracture.
In addition, the treatment group
variable was included in the
model for the combined analysis
only
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Our study has a number of strengths including the follow-
ing: (i) it has the largest population in an ongoing extension
study with a planned robust assessment of fracture as an out-
come; (ii) the decrease in fracture observed with the long-term
group was replicated in the cross-over group that was 3 years
older at the time of starting denosumab and observed within
the extension phase of the studymitigating the possible impact
of a cohort bias; and (iii) persistent low fracture rates were
observed through year 7.
Our study also has limitations, namely that, as is the case
for all extension studies, the original population may differ
from the cohort of subjects enrolled in the extension study
(potential selection bias) and the post hoc nature of the anal-
yses. In particular, by design, subjects were enrolled in the
extension provided they had received at least five out of six
denosumab or placebo doses over 3 years in FREEDOM and
at least five out of six denosumab doses in the first 3 years of
the extension for the cross-over group. Hence, the further
fracture risk reductions observed in year 4 of therapy and
beyond may not have been observed among subjects with less
than optimal persistence. In addition, while this extension en-
rolled a significant number of subjects, the small number of
events and the year-by-year variability remind us that some
degree of caution should exist in the interpretation of the data.
Attrition of subjects at high risk during the extension could
also influence the results; however, this is unlikely because (a)
the proportion of patients who sustained a fracture and
remained on study increased over time, and (b) the conclu-
sions remain valid even if we assume a fracture rate in those
who discontinued or died that is double that observed in the
remaining subjects [32]. Finally, these analyses cannot substi-
tute for the results of a randomized placebo-controlled study.
The need for an open-label extension study was predicated on
ethical concerns for continuing placebo treatment after
demonstration of denosumab anti-fracture efficacy in the
FREEDOM parent study.
In summary, in the ongoing extension to the FREEDOM
study, nonvertebral fracture rates were reduced during year 4
and beyond as compared with the first 3 years of denosumab
administration, a period for which robust fracture reduction is
already established. This observation appears distinctive to
denosumab administration for patients with osteoporosis and
who remain at risk for fracture based on bone densitometry.
Further confirmation of the benefits for nonvertebral fracture
protection in years beyond the fourth, or with regard to other
clinical parameters, awaits completion of all 10 years of the
FREEDOM extension study.
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